ライフサイエンスコーパス: SCr

1 SCr at 12 months was 1.6+/-0.7 in group 1 and 1.8+/-1.0

2 SCr decreased by 1.1 mg/dL in patients receiving terlipr

3 SCr in reversible AKI returned to baseline </=48 h after

4 SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 20

5 SCr level improved from baseline to day 14 on terlipress

6 SCr level in the early postischemic period (24-72 hr) se

7 SCr levels after contrast material administration are lo

8 SCr values were not statistically different late posttra

9 SCr-based and CrC-based scores were similar between grou

10 39 unique patients associated with 1,510,001 SCr values were identified.

11 dence of HRS reversal (defined as at least 1 SCr value </=1.5 mg/dL while on treatment), transplant-f

12 tions between renal function (estimated by 1/SCr and 1/CysC) and SBI, controlling for potential confo

13 rithmic GFR from the following covariates: 1/SCr, 1/SCr2, age, and sex (where SCr = serum creatinine)

14 imated by the inverse of serum creatinine (1/SCr); moderate renal impairment was defined as SCr > or

15 [CI] 1.09 to 1.32; P < 0.001) but not for 1/SCr (OR 1.08; 95% CI 0.98 to 1.19; P = 0.14), for which

16 Similarly, a 0.5-unit decrement in 1/SCr (equivalent to an increase in SCr from 1.0 to 2.0 mg

17 d by a flattening or positive slope of the 1/SCr plot and no graft loss.

18 ted with SBI (OR 1.26; P < 0.001), whereas 1/SCr was not (OR 1.06; P = 0.3).

19 Estimates based on 100/SCr and the new equation were the most precise.

20 fidence interval {CI}: 0.65, 1.86], P = .70; SCr >/= 0.3 mg/dL or 50% over baseline AKI definition od

21 rease or GFR decrease for 3 days after CT, a SCr increase (of >or=0.5 mg/dL [44.2 micromol/L, 25%] or

22 e of AR, as 32% of patients in group 4 had a SCr at 10 days after transplantation (SCr(10d)), before

23 No patient developed abnormal SCr levels (> 1.6 mg/dL [141 mumol/L]) as a result of th

24 um creatinine (SCr; peak SCr minus admission SCr) and categorized as no AKI (SCr change, <0.3 mg/dL),

25 of AHR, serum creatinine (SCr) level at AHR, SCr level after PP and IVIg at 3 months, days to achieve

26 s no AKI (SCr change, <0.3 mg/dL), mild AKI (SCr change, 0.3-<0.5 mg/dL), moderate AKI (SCr change, 0

27 (SCr change, 0.3-<0.5 mg/dL), moderate AKI (SCr change, 0.5-<1.0 mg/dL), and severe AKI (SCr change,

28 us admission SCr) and categorized as no AKI (SCr change, <0.3 mg/dL), mild AKI (SCr change, 0.3-<0.5

29 The incidence of AKI (SCr >/= 0.5 mg/dL above baseline) was compared between c

30 SCr change, 0.5-<1.0 mg/dL), and severe AKI (SCr change, >/=1.0 mg/dL).

31 econdary endpoint was defined as reaching an SCr value greater than 1.6 mg/dL.

32 <45, <30, 30-44, 45-59 mL/min/1.73 m(2)) and SCr (<1.5, >/=1.5, >/=1.6, >/=1.7, >/=1.8, >/=1.9, >/=2.

33 and TFF3 augmented the potential of BUN and SCr to detect kidney damage.

34 The CysC definitions and SCr definitions were similarly associated with clinical

35 0 mg/dL, those with SCr 1.0 to 1.4 mg/dL and SCr >1.4 mg/dL had an increased hazard ratio of death (u

36 ham surgery was induced in C57BL/6 mice, and SCr level and inulin clearance (Cin) were measured betwe

37 r); moderate renal impairment was defined as SCr > or = 1.3 mg/dl for women and > or = 1.5 mg/dl for

38 h all had substantial effects on the average SCr levels at discharge.

39 Baseline SCr may be misestimated in severe trauma patients becaus

40 itus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were compa

41 ial pressure correlated weakly with baseline SCr (r = 0.165, p = 0.03).

42 Because SCr is also a function of muscle mass, the authors deter

43 ile of CysC, whereas the association between SCr and SBI was U-shaped, with greater prevalence at hig

44 , we found a significant interaction between SCr and right atrial pressures (interaction P<0.0001); i

45 there was a significant relationship between SCr 6mo in paired recipients (P < 0.0008 by Spearman).

46 determined whether the relationship between SCr and dementia was particularly strong among individua

47 gnostic performance of urinary Kim-1 to BUN, SCr and urinary N-acetyl-beta-D-glucosaminidase (NAG) as

48 in these patients, which was not detected by SCr or estimated GFR alone.

49 d to have similar rates when reclassified by SCr levels at discharge.

50 ntrast material-induced nephrotoxicity (CIN; SCr increase >/=0.5 mg/dL [44.20 mumol/L] or >/=25%).

51 Iothalamate clearance, SCr, and creatinine clearance were obtained at each visi

52 eGFR <45 mL/min/1.73 m(2) instead of common SCr thresholds would significantly increase the number o

53 patients with prepregnancy serum creatinine (SCr) >150 micromol/L, a trend toward increased postpregn

54 ow a 6-month baseline of 1/serum creatinine (SCr) (slope of reciprocal creatinine) at or beyond 1 yea

55 oxicity in animal systems, serum creatinine (SCr) and blood urea nitrogen (BUN) are the primary optio

56 ed survival at seven days, serum creatinine (SCr) and blood urea nitrogen (BUN) daily for 3 days, and

57 Serum creatinine (SCr) and blood urea nitrogen (BUN) levels were evaluated

58 ent preclinical biomarkers serum creatinine (SCr) and blood urea nitrogen (BUN).

59 markers of renal function: Serum creatinine (SCr) and cystatin C (CysC).

60 ) is defined by changes in serum creatinine (SCr) and diuresis with risk/injury/failure/loss/end stag

61 iltration rate marker than serum creatinine (SCr) and may improve AKI definition.

62 inpatients with sufficient serum creatinine (SCr) data and stable renal function (difference between

63 inpatients with sufficient serum creatinine (SCr) data were identified.

64 g 9210 who had two or more serum creatinine (SCr) determinations, was evaluated.

65 of death, or pre-retrieval serum creatinine (SCr) greater than 1.5 mg/dl.

66 RD) performance to predict serum creatinine (SCr) in severe trauma population and determined the best

67 nvestigate the validity of serum creatinine (SCr) level as an indicator of postischemic renal dysfunc

68 dose of IVIg, time of AHR, serum creatinine (SCr) level at AHR, SCr level after PP and IVIg at 3 mont

69 as doubled on day 4 if the serum creatinine (SCr) level did not decrease by 30% of baseline.

70 pe 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3-3.3 mg/dl for women and 1.5-3.5 mg/dl

71 crease in maximal observed serum creatinine (SCr) level of either (a) >/=0.5 mg/dL (44.2 mumol/L) or

72 for CIN by using baseline serum creatinine (SCr) level.

73 n 228 patients with normal serum creatinine (SCr) levels (< or = 1.6 mg/dL [141 mumol/L]).

74 Serum creatinine (SCr) levels (mg/dl) were similar in all three groups at

75 Serum creatinine (SCr) levels and estimated glomerular filtration rate wer

76 ensitive and specific than serum creatinine (SCr) or blood urea nitrogen (BUN) in monitoring generali

77 by percentage increases in serum creatinine (SCr) over baseline.

78 t function was assessed by serum creatinine (SCr) values collected at early (mean, 50 days) and late

79 Daily (0-18) serum creatinine (SCr) values during and after the AR were plotted for eac

80 Mean discharge serum creatinine (SCr) values were computed after excluding patients who d

81 The mean discharge serum creatinine (SCr) was 2.7 (+/-2.5) mg/dl in the SCN recipients compar

82 Serum creatinine (SCr) was determined on entry into the study (initial PAH

83 jection (AR), and 12-month serum creatinine (SCr) were examined.

84 dge of an optimal expected serum creatinine (SCr) would be useful to detect early renal dysfunction a

85 bilization or reduction of serum creatinine (SCr), as evidenced by a flattening or positive slope of

86 en found to associate with serum creatinine (SCr), estimated glomerular filtration rate (eGFR) and/or

87 splant monitoring included serum creatinine (SCr), peripheral T-regulatory cells (pTregs)(127/CD4+/25

88 ., iothalamate clearance), serum creatinine (SCr)-based GFR estimates, or creatinine clearance.

89 ctive variables, including serum creatinine (SCr).

90 es (DSA) and acute rise in serum creatinine (SCr).

91 ted by similarly increased serum creatinine (SCr; approximately 4.5 mg/dl) at 2 days, tubule necrosis

92 using absolute changes in serum creatinine (SCr; peak SCr minus admission SCr) and categorized as no

93 nction (WRF) (upward arrow serum creatinine [SCr] >or=0.3 mg/dl) during treatment of decompensated HF

94 Incidence of AKI (serum creatinine [SCr] increase of >/=0.5 mg/dL [>/=44.2 mumol/L] above ba

95 ersal (CHRSR, defined as 2 serum creatinine [SCr] values </=1.5 mg/dL, at least 40 hours apart, on tr

96 ths after transplantation (serum creatinine [SCr]6 mo) and donor variables (P = 0.0004, analysis of v

97 This effect strengthened as pre-CT SCr increased.

98 ment of post-CT AKI for patients with pre-CT SCr levels of 1.6 mg/dL (141.44 mumol/L) or greater (odd

99 tion (difference between baseline and pre-CT SCr within 0.3 mg/dL and 50% of baseline) were identifie

100 s, and it increased with increases in pre-CT SCr.

101 Iodixanol decreased SCr (mean +/- standard deviation) from 1.77 mg/dL +/- 0.

102 In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patien

103 and with published guidelines (>/=2.0 mg/dL [SCr] and <45 mL/min/1.73 m(2) [eGFR]) using McNemar and

104 endpoints demonstrated similar results (eg, SCr >/=1.6 mg/dL [141.44 mumol/L] by using traditional C

105 Albumin outperformed either SCr or BUN for detecting kidney tubule injury and TFF3 a

106 Elevated SCr was associated with higher right atrial pressure and

107 An elevated SCr 6 mo was significantly associated with older donors,

108 However, an elevated SCr(10d) correlated with other potential risk factors fo

109 oth the donor and recipient, and an elevated SCr(10d) predicts a higher risk of acquiring additional

110 6), patients without AR but with an elevated SCr(6mo) (group 2, n=117), and patients with AR but low

111 ly worse in patients with AR and an elevated SCr(6mo) (group 4, n=165) compared with patients in the

112 The elevated SCr(6mo) in group 4 patients was not necessarily the con

113 linically indistinguishable with established SCr-defined criteria, suggesting that intravenous iodina

114 ulated MDRD equation is supposed to estimate SCr using a predetermined GFR of 75 mL/min/1.73 m.

115 Proportion of estimated SCr values that deviated less than 15%, 30%, or 50% was

116 Expected SCr correlated with the observed SCr in both living and

117 ed a formula to predict the optimal expected SCr after transplantation derived from donor and recipie

118 We compared the expected SCr with the lowest observed SCr in a cohort of living (

119 nfidence interval 1.73 to 3.71, P<0.0001 for SCr >1.4 mg/dL).

120 nfidence interval 1.26 to 2.17, P<0.0001 for SCr 1.0 to 1.4 mg/dL; unadjusted hazard ratio 2.54, 95%

121 ed AKI, and 0.66 and 0.58, respectively, for SCr-defined AKI.

122 2.04 (95% CI, 0.94-4.38), respectively, for SCr-defined AKI.

123 minated for CysC-defined AKI better than for SCr-defined AKI.

124 en the solitary and bilateral kidney groups (SCr >/= 0.5 mg/dL AKI definition odds ratio = 1.11 [95%

125 sed thresholds: 92.6% (26 285 of 28 390) had SCr <1.5 mg/dL; 91.3% (25 922 of 28 390) had eGFR of >/=

126 .5%) than in the iopromide group (27.8%) had SCr increase 0.5 mg/dL or higher (>or=25%, P = .012).

127 Two patients in each group had SCr increase of 1.0 mg/dL or more (not significant).

128 rate renal impairment, reflected by a higher SCr, is associated with an excess risk of incident demen

129 Among those in good-excellent health, higher SCr was associated with vascular-type dementia but not A

130 atients, but there were significantly higher SCr increments among group III patients after the 1 year

131 ctive IgG AECAs and had statistically higher SCr values and incidences of cellular rejection early po

132 However, SCr remained elevated compared with preischemia-reperfus

133 We assessed a change in SCr from baseline to 12 months as the primary efficacy v

134 Least squares mean percentage change in SCr from baseline to end of treatment did not differ bet

135 The placebo group had a mean+/-SD change in SCr from baseline to end of treatment of 0.33+/-0.67 mg/

136 nitial, defined as the incremental change in SCr from baseline to first postoperative measure.

137 e of > or = 25%, and the mean peak change in SCr.

138 The percentage changes in SCr after severe AKI are highly dependent on baseline ki

139 of AKI that incorporates absolute changes in SCr over a 24- to 48-h time period.

140 Modest changes in SCr were significantly associated with mortality, LOS, a

141 at 3 months, days to achieve 30% decline in SCr, and graft survival.

142 4% vs 13%, P = .008), defined by decrease in SCr level </=1.5 mg/dL.

143 eatment success was defined by a decrease in SCr level to </=1.5 mg/dL for at least 48 hours by day 1

144 Decreases in SCr and survival were correlated (r(2) = .882; P < .001)

145 ession analysis, a dose-related elevation in SCr levels was calculated.

146 se to therapy was assessed by improvement in SCr, histologic improvement, and decline in DSA strength

147 For example, an increase in SCr >or=0.5 mg/dl was associated with a 6.5-fold (95% co

148 ement in 1/SCr (equivalent to an increase in SCr from 1.0 to 2.0 mg/dl) was associated with a 26% inc

149 ociation with a nearly threefold increase in SCr level.

150 vealed a 0.015 mg/dL (1 mumol/L) increase in SCr levels per 100 mL CM.

151 Time to reach a 50% increase in SCr was directly related to baseline kidney function: Fr

152 t, the time to reach a 0.5-mg/dl increase in SCr was virtually identical after moderate to severe AKI

153 ther an absolute or a percentage increase in SCr.

154 Large increases in SCr concentration were relatively rare (e.g., >or=2.0 mg

155 patients), whereas more modest increases in SCr were common (e.g., >or=0.5 mg/dl in 1237 [13%] patie

156 duction in creatinine clearance, the rise in SCr was 246% with normal baseline kidney function, 174%

157 pressures (interaction P<0.0001); increased SCr best predicted death in patients with right atrial p

158 Iopromide increased SCr from 1.75 mg/dL +/- 0.32 (154.7 micromol/L +/- 28.29

159 (IgM) AECAs did not correlate with increased SCr or incidence of rejection.

160 year SCr (regression coefficient=0.02 for ln(SCr), P=0.3; 95%CI: -0.01 to 0.6).

161 roup 2, n=117), and patients with AR but low SCr(6mo) (group 3, n=185).

162 erent among patients without AR and with low SCr(6mo) (group 1, n=376), patients without AR but with

163 For each patient, the lowest SCr (oSCr) observed during the first week was used to es

164 Mean SCr of all groups was similar; however, pTregs were incr

165 Mean SCr was 1.05+/-0.35 mg/dL.

166 le there was an improvement (P=0.02) in mean SCr (2.4 mg/dL) at the end of therapy compared with SCr

167 In IRI mice, SCr level measured at 24, 48, and 72 hr after ischemia c

168 ean 1-week and 1-, 3-, 6-, 12-, and 18-month SCr levels were similar among groups.

169 Post-CT AKI with Acute Kidney Injury Network SCr criteria was the primary endpoint.

170 -CT AKI by using Acute Kidney Injury Network SCr criteria; the secondary endpoint was post-CT AKI by

171 All severe trauma patients with a normal SCr were retrospectively included between January 2005 a

172 old difference between expected and observed SCr that should trigger investigation and potential inte

173 The difference between expected and observed SCr was significantly greater among deceased donor kidne

174 the difference between expected and observed SCr, suggesting that recipient body weight is a major pr

175 ed the expected SCr with the lowest observed SCr in a cohort of living (79) and deceased (67) donor a

176 Expected SCr correlated with the observed SCr in both living and deceased donor kidney recipients,

177 Using eGFR <45 mL/min/1.73 m(2) instead of SCr of >/=1.5 mg/dL would result in a significant but sm

178 Measurement of SCr is practical and offers a simple way to noninvasivel

179 ) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respective

180 Rescue IS was started with rise of SCr/DSA/ rejection.

181 eGFR is associated with an increased risk of SCr-defined AKI following CT examinations.

182 g to the poor sensitivity and specificity of SCr and BUN, we used rat toxicology studies to compare t

183 Threshold of SCr >/=2.0 mg/dL could not be used to identify eGFR <30

184 iants, explaining 0.5% of the variability of SCr in Icelanders in addition to the 1% already accounte

185 Outcome measures were of SCr increase or GFR decrease for 3 days after CT, a SCr

186 ing Global Outcomes AKI definition (based on SCr or CysC).

187 These rare variants have a larger effect on SCr than previously reported common variants, explaining

188 acement therapy or liver transplantation) or SCr at or above baseline on day 4.

189 Kim-1 outperforms SCr, BUN and urinary NAG in multiple rat models of kidne

190 olute changes in serum creatinine (SCr; peak SCr minus admission SCr) and categorized as no AKI (SCr

191 and relative increases from baseline to peak SCr concentration during hospitalization.

192 e subgroup threshold analysis was performed (SCr <1.5 [<132.60 mumol/L]; >/=1.5 to >/=2.0 mg/dL [>/=1

193 Mean post-SCr increases were significantly less with iopamidol (al

194 The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over bas

195 Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular

196 ol/L, a trend toward increased postpregnancy SCr was identified.

197 Pre- and postprocedure SCr levels were assessed.

198 In patients with greater prepregnancy SCr and/or drug-treated hypertension during pregnancy, h

199 tions in SLC6A19 that associate with reduced SCr, three of which have been shown to cause Hartnup dis

200 ttransplant function rely on the recipient's SCr and calculations of estimated glomerular filtration

201 sk factor, but not in patients with a stable SCr level less than 1.5 mg/dL.

202 Patients with stable SCr less than 1.5 mg/dL (132.60 mumol/L) were not at ris

203 aneurysm, urinary Fg increased earlier than SCr in patients who developed postoperative AKI (AUC-ROC

204 UC-ROC=0.90), with a performance higher than SCr (AUC-ROC=0.73) and similar to cystatin C (AUC-ROC=0.

205 The SCr(10d) correlated weakly with graft survival (Cox, P=0

206 The SCr(10d) is an indicator of risk factors from both the d

207 The SCr-defined vs CysC-defined AKI incidence differed subst

208 ressed at 7 days despite suggestion from the SCr value that renal function is improving.

209 alculated that 64% of the variability in the SCr 6mo among patients was due to donor factors and 36%

210 tion we investigated the implications of the SCr(10d) concentration for graft prognosis.

211 In 11 (4.3%) patients, the SCr levels increased more than 25%, but all increases we

212 ith a protective effect against reaching the SCr threshold of 1.6 mg/dL (RR=0.80, P<0.001) beyond 12

213 had AR, that was equal to or higher than the SCr(6mo).

214 of racially dissimilar pairs showed that the SCr 6mo and graft survival 6 months after transplantatio

215 Compared with the SCr-based definition, the CysC-based definition is more

216 These SCr levels correlated with one- and five-year graft surv

217 72 hr and 7 days after ischemia, even though SCr level at 7 days was not different between control an

218 ndpoint was post-CT AKI by using traditional SCr criteria for contrast material-induced nephrotoxicit

219 had a SCr at 10 days after transplantation (SCr(10d)), before they had AR, that was equal to or high

220 reatinine at 6 months after transplantation (SCr(6mo) < or > or = 2 mg/dl).

221 However, at 1 year after transplantation, SCr was 1.4 +/- 0.2 in group I, 2.0 +/- 0.9 in group II,

222 Using SCr threshold of >/=1.5 mg/dL, identified inpatients had

223 Using SCr threshold of >/=2.0 mg/dL, identified inpatients had

224 f skin color on MELD scores calculated using SCr or corrected creatinine (CrC) in female candidates f

225 tion of Diet in Renal Disease formula, using SCr.

226 variates: 1/SCr, 1/SCr2, age, and sex (where SCr = serum creatinine).

227 2 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectiv

228 tional hazards analysis to determine whether SCr was an independent predictor of mortality.

229 enotyped individuals over the age of 18 with SCr measurements.

230 nces and all but one are rare (MAF <2%) with SCr effects between 0.085 and 0.129 standard deviations.

231 We tested the five variants associating with SCr for association with CKD in an Icelandic sample of 1

232 d loss-of-function variants associating with SCr in three solute carriers (SLC6A19, SLC25A45 and SLC4

233 ed the imputed variants for association with SCr.

234 4 mg/dL) at the end of therapy compared with SCr at the time of diagnosis (2.9 mg/dL), this improveme

235 Compared with patients with SCr <1.0 mg/dL, those with SCr 1.0 to 1.4 mg/dL and SCr

236 ith patients with SCr <1.0 mg/dL, those with SCr 1.0 to 1.4 mg/dL and SCr >1.4 mg/dL had an increased

237 5% CI: 0.26-2.7 for group 2 vs. 1) or 1-year SCr (regression coefficient=0.02 for ln(SCr), P=0.3; 95%

238 Mean 3-month and 1-year SCr levels were 1.9 and 1.8, respectively, in the remain